eligibility_summary
Eligibility: Adults ≥18 with histologically confirmed TNBC (HER2−, ER/PR <1%) or HR+/HER2− (HR ≥1%), locally advanced, recurrent, or metastatic, not resectable, planned sacituzumab govitecan (SG) mono/comb therapy, consent/compliance. Exclude: pregnancy/lactation, SG allergy, other cancers within 5 yrs (except certain cured types or cured ≥5 yrs), other trials, serious infection/organ failure, psychiatric noncompliance, SG change not due to progression, investigator-deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study: Observational, real-world evaluation of sacituzumab govitecan (SG) as monotherapy or in combinations in unresectable locally advanced, recurrent, or metastatic HER2‑negative breast cancer (TNBC and HR+/HER2- cohorts). Drug/intervention and mechanism: SG is a targeted antibody–drug conjugate (humanized IgG) against Trop-2, carrying SN-38, the active metabolite of irinotecan (a topoisomerase I inhibitor). After Trop-2 binding and internalization, a cleavable linker releases SN-38, inducing topoisomerase I–mediated DNA damage, replication stress, and tumor cell death, extracellular release can confer a bystander effect. Targets: Trop-2–expressing breast cancer cells, DNA replication/topoisomerase I pathway. Combination partners are per real-world practice (unspecified).